Recce has recently attracted attention because it’s advancing drug candidates against serious infections, a space with significant potential if late-stage trials succeed. That kind of promise is why some market watchers see upside in RCE’s shares. On the flip side, the company remains unprofitable, with no consistent earnings or predictable cash flow, so it’s still a speculative biotech rather than a stable performer.
Cettire (ASX: CTT) share price recently had a breakout. But it is in a bit of limbo; enough promise remains that a rebound could be on the cards, but enough uncertainty that it’s far from a safe bet. On one hand, the company is forecast to post healthy earnings-per-share growth over the next few years and has a pretty low price-to-sales ratio compared with peers, suggesting some latent value. On the other hand, consensus analyst targets hover modestly, some even see a drop, and many believe any upside beyond roughly one Australian dollar a share depends on improvements that aren’t guaranteed.
The small-cap medical-tech company, Control Bionics, has just taken steps that could catapult it far beyond its current size. Its core product, a wearable sensor that translates even the faintest muscle or nerve signals into computer commands, is already approved and helps people with severe physical disabilities communicate and interact. Recently, the company announced that it had integrated a significant tech giant’s brain-computer interface protocol into its devices.
Investigator Silver (ASX: IVR), formerly known as Investigator Resources, is moving through one of the most strategically important phases in its history. The company is advancing the Paris Silver Project, Australia’s highest-grade undeveloped primary silver deposit, while simultaneously delivering exploration wins across its 100%-owned Peterlumbo tenement and progressing copper-gold targets at Uno Morgans.
When you spend enough time around the ASX, you start to notice a certain rhythm in how strong charts behave. Some stocks creep for weeks, building energy in tight ranges, and then, almost without announcement, they begin flashing early signs of strength. In this review, we focus on three ASX-listed companies whose price action suggests further upside.
When you track the ASX day after day, you eventually spot those moments when a stock stops drifting and suddenly kicks into gear. A clear breakout, the kind that pushes past weeks of hesitation, often tells you buyers are finally taking control. In this article, we’re looking at three Australian companies whose share prices have recently surged through key resistance levels. These aren’t just quick spikes or one-day wonders. Each chart shows a pattern of tightening ranges, rising volume, and a decisive move that suggests momentum may continue.
